• Pivotal Phase 3 AML trial to commence, bridging RC110 to RC220
• NSCLC trial in advanced planning to leverage (E,E)-bisantrene's G4-binding mechanism
• Continued focus on cardioprotection/anticancer opportunity of RC220 with doxorubicin

Race Oncology Ltd is pleased to announce two new clinical trials for RC220 in Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC). The discovery that (E,E)-bisantrene, the active drug in RC220, is a DNA/RNA G-quadruplex (G4) binder has identified a major clinical and commercial opportunity for RC220 in mutated epidermal growth factor receptor (EGFRm) driven NSCLC. Race has initiated a new clinical program in NSCLC to leverage the unique molecular mechanism of action of (E,E)-bisantrene to potentially address the urgent unmet patient need for better treatment options for acquired EGFR tyrosine kinase inhibitor (TKI) resistance. In addition, Race Oncology has identified a rapid and cost-effective clinical pathway to potential regulatory approval of RC220 in relapsed/refractory AML, including a bridging and dose optimisation stage. Race's clinical focus on the cardioprotective and anticancer activity of RC220 in combination with doxorubicin remains a clear priority, with the ongoing Phase 1a/b trial of significant value for both patients and shareholders.

Race remains well financed with cash and cash equivalents of $11.3m at 30 September 2025 and is fully funded to undertake all existing trials and other programs until mid 2027 from current funds.

Race is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.